Parallax Volatility Advisers’s Cymabay Therapeutics CBAY Stock Holding History

Parallax Volatility Advisers’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-56	Closed	-$1K	–	4175
2018 Q3	$1K	Sell	56 -2,582	-98%	-$32.1K	﹤0.01%	2500
2018 Q2	$35K	Buy	2,638 +1,324	+101%	+$16.6K	﹤0.01%	1671
2018 Q1	$17K	Sell	1,314 -186	-12%	-$2.31K	﹤0.01%	1738
2017 Q4	$14K	Hold	1,500	–	–	﹤0.01%	3755
2017 Q3	$12K	Buy	+1,500	New	+$10.1K	﹤0.01%	1737
2017 Q1	–	Sell	-1,764	Closed	-$3K	–	4865
2016 Q4	$3K	Hold	1,764	–	–	﹤0.01%	2899
2016 Q3	$3K	Sell	1,764 -5,610	-76%	-$11.2K	﹤0.01%	2754
2016 Q2	$13K	Sell	7,374 -17,900	-71%	-$37.1K	﹤0.01%	2351
2016 Q1	$34K	Hold	25,274	–	–	﹤0.01%	2217
2015 Q4	$43K	Buy	25,274 +1,874	+8%	+$3.06K	﹤0.01%	2387
2015 Q3	$45K	Hold	23,400	–	–	﹤0.01%	2205
2015 Q2	$63K	Buy	+23,400	New	+$96.1K	﹤0.01%	2443

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parallax Volatility Advisers's CBAY Position: Q4 2018 in Review

Parallax Volatility Advisers sold out of Cymabay Therapeutics (CBAY) in Q4 2018, closing a stake of 56 shares — an estimated $1K sold.

Parallax Volatility Advisers first reported a position in CBAY in Q2 2015 and held it in 12 quarters. The position peaked at $63K in Q2 2015. 131 funds tracked by Wall St. Rank hold CBAY as of Q4 2018.

Parallax Volatility Advisers reported no remaining Cymabay Therapeutics position as of Q4 2018 after selling out during the quarter.
Parallax Volatility Advisers sold 56 Cymabay Therapeutics shares in Q4 2018, an estimated $1K.
Parallax Volatility Advisers first reported a position in Cymabay Therapeutics in Q2 2015 and held it in 12 quarters.
Parallax Volatility Advisers's Cymabay Therapeutics position peaked at $63K in Q2 2015.
131 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2018.

Based on Parallax Volatility Advisers's 13F filing for Q4 2018, filed 14 Feb 2019.